Trial enrollment benchmarks, 2015–2025
75% of industry Phase 2–3 trials miss their enrollment target
Pick your phase and therapeutic area to see how trials like yours did. We measured 11,858 trials against the enrollment plan each one registered on day one.
- 25,437trials reviewed in ClinicalTrials.gov record history
- 11,858measured against their registered plan
- 813checked against peer-reviewed publications
Industry Phase 2–3 trials, US and ex-US sites
For every 100 trials, 25 hit their enrollment target
Target: enrollment closed by the date planned at registration, with at least 90% of planned patients, and the trial not terminated. From 25,437 trials reviewed; the headline covers the 3,294 industry-sponsored Phase 2–3 trials with US and ex-US sites measured against their registered plan.
- 25hit target
- 65closed enrollment late
- 10closed on time, but short of goal or terminated
- 79%of misses ran the enrollment window long
- 9 monthsthe median time late at enrollment close for trials that closed late (middle half 4–18)
- 19%of completed trials enrolled under 90% of the original target
Source: ClinicalTrials.gov record history. Data as of October 2026.
Trials that closed enrollment late
Late trials finished enrollment a median 9 months behind plan
65% of industry Phase 2–3 trials closed enrollment after the date planned at registration. 54% of late trials started late and enrolled slowly, 38% started on time and enrolled slowly, and 9% were late only because they started late.
Months behind the registered plan
Medians for trials that closed enrollment late
- Late at enrollment close9 months
middle half 4–18 months
- Enrollment window longer than planned8 months
middle half 3–16 months
Months behind the registered plan
- Median
- Middle half of late trials
A shorter-than-planned enrollment window counts as zero. The middle half runs from the 25th to the 75th percentile of trials that closed late.
Why misses happen
Share of trials that missed target; reasons overlap
- Enrollment window ran long79%
- Started late62%
- Closed short of goal16%
- Terminated early24%
Industry Phase 2–3 trials, US and ex-US sites
Hit rates run from 14% in GI/hepatology to 40% in dermatology
Share of trials that closed enrollment on time with at least 90% of planned patients, by therapeutic area. Oncology is the largest group, at about 420 trials.
Hit target, by therapeutic area
Measured trials shown at right, rounded to 10
- Dermatology40%≈350
- Metabolic/Endocrine38%≈310
- Pain32%≈30
- Immunology/Rheumatology29%≈290
- Ophthalmology28%≈120
- Cardiovascular27%≈170
- Respiratory26%≈240
- Musculoskeletal22%≈60
- Infectious disease21%≈250
- Women’s health19%≈30
- Neurology19%≈360
- Oncology19%≈420
- Hematology (non-malignant)18%≈140
- Psychiatry16%≈130
- Renal/Urology14%≈110
- GI/Hepatology14%≈270
All areas: 25%
Hit target, by phase
All therapeutic areas
- Phase 220%≈1,450
- Phase 2/312%≈140
- Phase 330%≈1,700
Phase 2–3 overall: 25%
Your phase, your area, your sponsor type
The benchmark below breaks these numbers down further: geography, sponsor type and planned enrollment, plus why trials like yours miss and how many months they lose.
Benchmark your studyBy planned completion year
The miss rate has held between 67% and 83% every year
Eleven years of industry Phase 2–3 trials, grouped by the year each planned to complete. Missed target ranged from 67% in 2018 to 83% in 2022; 74% in 2025. Closed enrollment late ranged from 59% to 72%.
Share of trials, 2015–2025
Missed target ranged from 67% in 2018 to 83% in 2022; 74% in 2025. Closed enrollment late ranged from 59% to 72%.
- Missed target
- Closed enrollment late
- Range of the miss rate
| Year | Missed target | Closed enrollment late |
|---|---|---|
| 2015 | 75% | 67% |
| 2016 | 69% | 62% |
| 2017 | 68% | 62% |
| 2018 | 67% | 59% |
| 2019 | 71% | 63% |
| 2020 | 74% | 63% |
| 2021 | 80% | 68% |
| 2022 | 83% | 72% |
| 2023 | 80% | 70% |
| 2024 | 80% | 66% |
| 2025 | 74% | 63% |
Hover a year for its values. Trials are counted in the year their registered primary completion was planned.
How we measured
Measured against the plan each sponsor registered on day one
Every US-site Phase 1–3 drug and biologic trial enrolling patients, with planned completion from 2015 to 2025, read from the full ClinicalTrials.gov version history: 25,437 trials reviewed, 11,858 measured against their registered plan.
Planned enrollment close is the registered primary completion date minus the primary-endpoint follow-up. A trial hits target when enrollment closes on or before that date with at least 90% of planned patients and the trial is not terminated.
- Hit target
- Enrollment closed by the planned date, with at least 90% of planned patients, and the trial was not terminated.
- Closed late
- Enrollment closed after the date planned at registration.
- On time, but short
- Enrollment closed by the planned date but under 90% of the planned patients, or the trial was terminated.
- Not in the headline
- Dose-finding (Phase 1 and 1/2) trials, and trials sponsored by academic centers, hospitals, NIH/NCI or other government bodies. US-only industry trials appear as a separate view. The benchmark tool includes all of them.
Validation
813
trials checked in total against peer-reviewed publications that report their enrollment
Closed enrollment late
389 headline-scope trials with a published paper
- Registry, this benchmark59%
- Published papers72%
Under 90% of target
469 headline-scope trials with a published paper
- Registry, this benchmark9%
- Published papers19%
The registry records fewer late closures than the publications, so the lateness figures on this page are a floor.
Benchmarks describe historical trials and do not predict any single trial. Counts in the charts are rounded to the nearest 10; groups with fewer than 20 measured trials are not shown. Months late are medians for trials that closed late; a shorter-than-planned enrollment window counts as zero.
Your study
See how trials like yours performed
Choose your phase and therapeutic area to see the trials on record, then add your work email to open the full benchmark: hit rate and late-close rate, why trials like yours missed, months late, and filters for geography, sponsor type and planned enrollment.